CRISPR QC and Cardea Bio CRISPR-BIND
CRISPR quality control testing firm CRISPR QC and Cardea Bio have launched CRISPR-BIND, a rapid and highly sensitive tool to characterize guide RNA and CRISPR-Cas interactions. CRISPR-BIND is the first product in a suite of quality control capabilities, and is built on Cardea's biology-gated transistors and an automated, high-throughput liquid handler to generate highly sensitive electronic signals that allow for rapid assessments of gRNA-Cas interactions directly at the bench. This includes, but is not limited to, monitoring the interactions and stability of a variety of modified gRNAs with engineered Cas enzymes.
CRISPR QC will commercialize CRISPR-BIND in the US in partnership with COBO Technologies, which will offer the product in Europe, the firms said. CRISPR QC is Cardea's first commercial partner and CRISPR-BIND is the first of a series of CRISPR QC applications that they expect to come out of the partnership.
Seven Bridges RHEO Visual Interface for Multi-Omic Analysis
Seven Bridges has introduced the RHEO Visual Interface workflow automation tool for multi-omic analysis. RHEO can completely auto-generate a visual interface from a developer's automation script, and complements the existing command line interface for automations releases by the company last year. The interface minimizes the time and effort required to set up and run data-analysis workflows for biologists, particularly those who work with experimental data but do not have extensive training in workflow automation, Seven Bridges said. Additional benefits include installation-free use, automatic authentication, instant collaboration, comprehensive audit logs, versioning and 100 percent reproducibility, all within a secure and compliant cloud environment, the company added.
Congenica COVID-19 Module
Congenica has added a COVID-19 module to its genomic analysis platform. The company said that the new add-on will support research into relationships between a patient's genome and COVID-19 infection risk, severity, and clinical outcomes. The module also helps researchers prioritize variants in curated genes based on Human Phenotype Ontology terms that suggest COVID-19 symptoms.
For more new products and services, please visit the New Products page on our website.